Multilocus hereditary cancer: A case series of patients with pathogenic variants in three distinct genes

ACMG 2026

Mar 10, 2026
Oncology
Presentation

Asma Ali, Madaline Purfeerst, Joan Steyermark, Kara Eckberg, Laura Ongie, Larissa Veres, Radhika Dhamija

Introduction
Germline pathogenic variants are implicated in approximately 10% of adult solid-tumor cancers, and the use of next-generation sequencing (NGS)-based multigene panel testing is widely accepted and practiced. Identifying pathogenic variants (PV) in cancer predisposition (CP) genes enables personalized risk assessment, targeted surveillance, and risk-reducing interventions. Increasingly, literature reports describe individuals harboring PV in two or more CP genes. We present a case series of five patients found to carry PV in three distinct CP genes.

 

Methods
We performed a retrospective chart review of patients seen in the Department of Clinical Genomics at Mayo Clinic’s Rochester site between 2021 and 2025. Inclusion criteria were: (1) completion of genetic counseling and multigene panel testing, and (2) identification of PV in three or more CP genes. Data was extracted from the electronic health record. Variables collected included age, sex, indication for testing, germline panel completed, testing laboratory, sample type, personal and family history (FH) of cancer, variant details and inheritance patterns.

 

Results
Five patients met inclusion criteria. All underwent multigene panel testing.

 

•

 

Case 1: Male, age 75, tested at age 71 due to personal history of colorectal, renal, and prostate cancer, multiple myeloma (in complete remission for 5 years) and FH of cancer. Panel testing included 47 genes via Invitae; sample type: gDNA from skin fibroblasts. PV in BRCA1 (c.2071del), a likely pathogenic variant (LPV) in ATM (c.8010+2T>G), and LPV in CHEK2 (c.190G>A) were detected.

 

•

 

Case 2: Female, age 63, tested at age 61 due to personal history of breast cancer, FH of cancer and siblings with PV in BRCA1, ATM and CHEK2. Panel testing included 47 genes via Invitae; sample type: gDNA from blood leukocytes. PV in BRCA1 (c.2071del), LPV in ATM (c.8010+2T>G), and LPV in CHEK2 (c.190G>A) were detected.

 

•

 

Case 3: Female, age 39, tested due to clinical diagnosis of NF1 and FH of breast cancer. Panel testing included 21 genes via Invitae; sample type: gDNA from blood leukocytes. PV in BRCA2 (c.9253dup), RAD51D (c.803G>A), and NF1 (c.6792C>A) were detected.

 

•

 

Case 4: Female, age 23, tested due to clinical diagnosis of NF1 and PV identified on NGS based panel on bone marrow sample performed for indication of chronic eosinophilia. Panel testing included 76 genes via Ambry Genetics; sample type: gDNA from blood leukocytes. PV in BRCA2 (c.574_575delAT), NF1 (c.5944-5A>G), and SDHA (c.91C>T) were detected.

 

•

 

Case 5: Female, age 43, tested due to personal history of mantle cell lymphoma and FH of cancer. Panel testing included 125 genes via Invitae; sample type: buccal swab. PV in ATM (c.9022C>T), CHEK2 (c.1100delC), and LPV in KIT (c.1541-1G>A) were detected.

 

All variants were heterozygous with autosomal dominant inheritance. All patients received personalized management recommendations and were offered cascade testing for at-risk relatives.

 

Conclusion
This retrospective analysis highlights the clinical utility of genetic testing in identifying complex hereditary cancer syndromes at a single tertiary care center. Our study characterizes a unique cohort with multiple hereditary cancer risks and suggests potential advantages of multigene panel testing over more targeted approaches. Interestingly, some PV were identified without suggestive FH, which could reflect reduced penetrance, de novo events, or parent-of-origin effects. Notably, two of five patients had NF1 in addition to PV in CP genes, and given NF1’s prevalence, a second genetic disorder in NF1 patients is not unexpected. Currently, no standardized protocols exist for surveillance or risk-reducing strategies in patients with multiple PV in CP genes. Existing National Comprehensive Cancer Network (NCCN) guidelines address hereditary cancer risks individually and do not account for the presence of multiple PV. This gap presents a challenge for clinicians and emphasizes the need for updated and integrated recommendations.